Although several subgroups (e.g., RASI co-users and heart failure-free patients) did not reach statistical significance, no subgroup demonstrated a higher risk of AKI with SGLT2i.
← all excerpts
Effects of SGLT2 inhibitors on NSAID-associated acute kidney injury in type 2 diabetes: a claims-based cohort study.
1
—
—